Factsheet
February 12, 2019

Early Hit-to-Lead ADME Screening Bundle

Bundled Screening Assays to Accelerate Candidate Selection in Drug Discovery
In vitro ADME screening during the lead optimization stage of drug discovery positively impacts drug candidate selection with an enhanced probability of success in clinical trials. Since most new drug candidates fail during preclinical and clinical development, and the late stage of the drug development cycle can be a lengthy and costly process, any means of identifying drug candidates with optimized ADME and pharmacokinetics properties in the discovery stage will have a significant impact on the drug discovery process overall. 

Our scientists routinely conduct industry standard in vitro metabolism and DDI-based assays, including highly automated ADME in vitro screens. We can help drive your discovery phase structure activity relationship (SAR) by optimizing for ADME properties, in parallel to your receptor binding potency and selectivity, for more rapid identification of high quality drug candidates. 

Metabolic stability, risk assessment for inhibiting key Cytochrome P450 enzymes, and cell permeability are three main early hit-to-lead ADME screening assays that all new chemical entities (NCEs) are tested for in the industry in effort to optimize key ADME properties.

Download our factsheet to learn more about our early hit-to-lead ADME screening bundle.

Related Services:
High-Throughput ADME Screening Services

Capabilities that accelerate preclinical studies

Bioanalytical & ADME Laboratory Services

Accelerate and enhance your discovery, preclinical and clinical programs

In Vitro ADME & Metabolite Identification Services List

Services to support your In Vitro ADME development needs

Read More